Durvalumab after SBRT reduces tumour progression in early-stage NSCLC

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

EAU 2026: Updates in NMIBC

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival